METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours
João Glasberg1,2, Aley Talans3,4, Thomás Rivelli Giollo1, Débora Zachello Recchimuzzi1, João Evangelista Bezerra Neto1, Rossana Veronica Mendonza Lopez5, Paulo Marcelo Gehm Hoff1 and Rachel P Riechelmann2,6
ecancer 16 1369 (2022) https://doi.org/10.3332/ecancer.2022.1369
1Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil
2Post Graduate Program, Faculdade de Medicina da Universidade de São Paulo, Brazil
3Department of Medical Radiology, Fleury Group, São Paulo, Brazil
4Department of Medical Radiology, Hospital Israelita Albert Einstein, São Paulo, Brazil
5Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil
6Department of Clinical Oncology, AC Camargo Cancer Center, São Paulo, Brazil
Keywords: neuroendocrine tumours, metformin, cancer treatment
Correspondence to: Rachel P Riechelmann
Email: rachel.riechelmann@accamargo.org.br
Published: 04/07/2022
Received: 14/06/2022
Publication costs for this article were supported by ecancer (UK Charity number 1176307).
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thomás Rivelli Giollo is corrected to Thomás Giollo Rivelli
